Navigation Links
Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer
Date:8/6/2009

HOUSTON, Aug. 6 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is being conducted under a Bellicum Investigational New Drug application allowed by the FDA in 2008. The company anticipates reporting initial results of the study in 2010.

BP-GMAX-CD1 is a novel cancer vaccine that can be precisely activated at an optimal time and location in the body. It is produced by genetically modifying autologous antigen-loaded dendritic cells to express an inducible costimulatory CD40 (iCD40) receptor. Twenty-four hours after intradermal administration, these genetically modified dendritic cells are activated in draining lymph nodes by intravenous administration of AP1903, a small-molecule dimerizer agent developed by ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA). In this way, the immune system's innate homeostasis is overridden and a potent and durable antigen-specific T cell response may be generated.

The dose-escalation trial will evaluate the safety of BP-GMAX-CD1 and AP1903 in a minimum of 24 patients with androgen independent prostate cancer (also known as castrate resistant prostate cancer or CRPC). Six doses will be administered on a weekly or every other week schedule, with responses assessed at week 13. Patients whose disease has not progressed at the end of this acute phase will be eligible to receive booster vaccinations every eight weeks for up to one year. Exploratory efficacy endpoints include prostate-specific antigen dynamics, circulating tumor cell count, antigen-specific immune response, and clinical response. Additional information can be found at www.clinicaltrials.gov.

Bellicum Founder, President and Chief Medical Officer, Kevin M. Slawin, M.D., stated, "This first clinical trial of BP-GMAX-CD1 is designed to establish proof of principle for our core iCD40 technology, which has been engineered to overcome the critical potency limitations of previous cancer vaccine strategies. Dosing the first patient is an exciting and significant milestone in our quest to deliver safer and more effective therapies to patients with advanced cancer."

The small-molecule dimerizer, AP1903, and the ARGENT(TM) cell-signaling regulation technology underlying BP-GMAX-CD1 were licensed from ARIAD Pharmaceuticals, Inc. AP1903 is designed to bring together two proteins and activate them. In the case of BP-GMAX-CD1, administration of AP1903 to patients leads to controlled activation of the ARGENT-regulated protein iCD40. AP1903 was previously shown by ARIAD to be well-tolerated with defined pharmacokinetics in a Phase 1 clinical trial.

"This is an exciting application of ARIAD's dimerizer technology, with the potential for therapeutic benefit linked to precise control of signaling events inside cells," stated Timothy P. Clackson, Ph.D., Senior Vice President and Chief Scientific Officer of ARIAD. "We congratulate Bellicum on this first application of the dimerizer technology in cancer patients."

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response. The company's lead product, BP-GMAX-CD1, a genetically modified, pharmacologically regulated autologous vaccine, is in clinical development for patients with advanced, androgen independent prostate cancer. BP-GMAX-CD1 and follow-on product candidates have been successfully tested in mouse models and human dendritic cells. The company owns or has in-licensed certain key technologies, and Chief Executive Officer Thomas J. Farrell has assembled a team of seasoned clinical, regulatory, quality and CMC consultants to advance product candidates into human clinical trials. For more information, visithttp://www.bellicum.com


'/>"/>
SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bellicum Pharmaceuticals Announces $3.75 Million in Financing
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The narrative ... offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes the ... disorder and his attempts to overcome them. , Schanssema, initially unsure of the ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State ... convening academic faculty engaged in or interested in palliative care education and research. The ... be held in North County San Diego on Sept. 28 and 29, 2017, on ...
(Date:2/24/2017)... , ... February 24, 2017 , ... The International Association ... annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected from ... be showcased and the winner revealed at the 31st annual iaedp Symposium, March 22 ...
(Date:2/24/2017)... ... ... The Radiology Business Management Association will select the 2017 Quest ... Better Radiology Marketing Programs conference, held this year from March 5 to 7 ... given out in five categories. They are:, ,     Patient Marketing, a ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... qualifying into the Senior International Elite division on February 12th. Ms. Esparza ... divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida is ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the Cowen and Company 37 th ... Copley Place on Tuesday, March 7, 2017 at 11:20 ... of the presentation can be accessed at http://wsw.com/webcast/cowen38/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/24/2017)... Research and Markets has announced the addition of the "Hemophilia Drugs ... ... Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks ... What are the key drugs marketed for ... Hemophilia market? What are the unit prices and annual ...
(Date:2/24/2017)... HARRISBURG, Pa. , Feb. 24, 2017 ... Secretary of Drug and Alcohol Programs Jennifer Smith ... role in providing training for and using naloxone, a ... Mark McCullough , a recovery specialist and overdose ... naloxone by EMS providers. "A significant part ...
Breaking Medicine Technology: